2026 State Pharmacy Law Changes: Which States Updated Their MPJE Content

Why State Law Changes Matter for Your MPJE

The MPJE tests pharmacy law as it exists at the time of your exam — not the version covered in last year's study materials. State legislatures pass new pharmacy laws every session, and state boards of pharmacy issue rule updates throughout the year. Candidates who rely on outdated materials risk encountering questions about laws their resources have not yet covered.

This article tracks the most significant state pharmacy law changes from 2025–2026 that are most likely to appear on MPJE exams. Always verify current law with your State Board of Pharmacy before your exam date.

Pharmacist Prescribing Authority Expansions in 2025–2026

The trend toward expanded pharmacist prescribing authority accelerated significantly in the 2025–2026 legislative cycle. The following expansions are the most exam-relevant:

Hormonal Contraceptives

Multiple states now authorize pharmacists to prescribe and dispense hormonal contraceptives (oral contraceptives, patches, rings, injectables) without a physician prescription. This authority was already established in California, Oregon, Colorado, and New Mexico, and additional states followed in 2025–2026. MPJE candidates in these states must know: the screening requirements before dispensing, mandatory referral criteria, documentation obligations, and whether a collaborative practice agreement is required or if independent authority applies.

PrEP and PEP for HIV Prevention

Several states now allow pharmacists to initiate PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) for HIV prevention. California was the first to authorize this; other states are following. Know whether your state requires a CLIA-waived HIV test before initiating PrEP and what the mandatory follow-up requirements are.

Naloxone and Opioid Overdose Reversal

All 50 states now have some form of naloxone access law. The key distinctions being tested on the MPJE are: Does your state require an individual prescription, or can pharmacists dispense under a statewide standing order? What are the pharmacist immunity provisions? What documentation is required? Know your specific state's naloxone dispensing rules in detail.

PDMP Requirement Changes 2025–2026

Prescription Drug Monitoring Program requirements continued to tighten across states in 2025–2026. The most common changes affecting MPJE content include:

• Expanded mandatory query triggers: Several states expanded PDMP query requirements from Schedule II only to include Schedule III and IV, or expanded to require queries for any opioid or benzodiazepine regardless of schedule.
• Delegate access: Most states now allow pharmacist interns and technicians to query the PDMP on behalf of a pharmacist, but the pharmacist retains responsibility for reviewing results. Know your state's delegate rules.
• Interstate data sharing: PMP InterConnect now connects PDMPs across 50+ jurisdictions. Pharmacists in participating states must query interstate data for high-risk patients. Know whether your state mandates interstate queries.
• Real-time reporting: Several states shortened the window for pharmacies to report dispensing data to the PDMP — from 72 hours to 24 hours or even same-day in some jurisdictions.
• Mandatory PDMP integration: Some states now require pharmacy dispensing software to be integrated directly with the state PDMP, eliminating the separate login step.

Opioid Prescribing Limits — State Rules

A majority of states have now enacted acute pain opioid prescribing limits — typically restricting initial prescriptions for acute pain to 7 days (some states: 5 days). Key exam points:

• Most limits apply to initial prescriptions for acute pain — not cancer pain, chronic pain, palliative care, or hospice.
• Pharmacist's responsibility: If a prescription exceeds the limit, the pharmacist should contact the prescriber. In most states, the pharmacist should not dispense more than the legal limit without a documented clinical justification.
• Day supply calculation: Know how your state calculates a "day supply" for opioids when the directions call for PRN (as needed) dosing.
• Specific state variations: Ohio (7 days), Florida (3 days for acute, 7 days for sub-acute), New Jersey (5 days initial), New York (7 days initial). Know your state's specific limit.

Collaborative Practice Agreement Updates

For your MPJE: Know whether your state requires a CPA for pharmacist prescribing, what the CPA must contain (supervising physician, patient population, drug therapy protocols, documentation), how the CPA is initiated and maintained, and what activities pharmacists can perform under a CPA vs. independently.

Controlled Substance Schedule Changes

DEA and state boards periodically add, remove, or reschedule controlled substances. Recent additions that have appeared in MPJE questions:

• Xylazine: DEA added xylazine (a veterinary sedative increasingly found in the illicit drug supply) to Schedule III in 2024. Know its classification.
• Tramadol: Remains Schedule IV federally. Some states have placed it in a more restrictive state schedule — verify your state's classification.
• Buprenorphine products: Regulatory changes around buprenorphine prescribing for opioid use disorder (DATA 2000 waiver elimination in 2023 — any DEA-registered practitioner can now prescribe buprenorphine for OUD). Know the current rules.
• Cannabis: Remains Schedule I federally despite state-level legalization in many jurisdictions. Pharmacists cannot dispense cannabis as a prescription product under any circumstances per federal law, regardless of state law.